On March 3, 2016, the SEC instituted settled cease-and-desist proceedings against Nordion (Canada) Inc. According to the SEC: "From at least 2004 through 2011, Nordion, Inc. ('Nordion'), a global health science company, violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act of 1977 ('FCPA') in connection with payments made to a third party agent to obtain Russian government approval to distribute TheraSphere, Nordion's liver cancer treatment, in Russia. Nordion failed to record those payments in a manner that accurately and fairly reflected the transactions in its books and records. Nordion also failed to devise and maintain adequate internal accounting controls to provide sufficient reassurances that Nordion funds were used as authorized, that third-party agents were appropriately vetted, and that Nordion adequately trained its employees to conduct business in countries with significant corruption risks." The SEC stated that: "Respondent acknowledges that the Commission is not imposing a civil penalty in excess of $375,000 based upon its and Nordion's cooperation in a Commission investigation and related enforcement action."